ReviewVirulence2014
Middle East respiratory syndrome (MERS): a new zoonotic viral pneumonia.
Review in Virulence, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 129 citations in OpenAlex.
- Profile of Circulatory Cytokines and Chemokines in Human Coronaviruses: A Systematic Review and Meta-Analysis.Frontiers in immunologyPooled it
- A metagenomic investigation of the faecal RNA virome structure of asymptomatic chickens obtained from a commercial farm in Durban, KwaZulu-Natal province, South Africa.BMC genomics · 2024Article
- Stokes-Mueller polarization-based analysis of model SARS-CoV-2 virions.Lasers in medical science · 2023Article
- Article
- Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice.Human immunology · 2022Review
- Molecular biology of the SARs-CoV-2 spike protein: A review of current knowledge.Journal of medical virology · 2021Review
- SARS-CoV-2 spillover transmission due to recombination event.Gene reports · 2021Article
- Lymphocyte subsets early predict mortality in a large series of hospitalized COVID-19 patients in Spain.Clinical and experimental immunology · 2021Article
- Washed microbiota transplantation in patients with respiratory spreading diseases: Practice recommendations.Medicine in microecology · 2021Article
- Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2.Human vaccines & immunotherapeutics · 2021Article
- Ocular tropism of coronavirus (CoVs): a comparison of the interaction between the animal-to-human transmitted coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS-CoV, CoV-229E, NL63, OC43, HKU1) and the eye.International ophthalmology · 2021Review
- Factors associated with acceptance of COVID-19 vaccine among University health sciences students in Northwest Nigeria.PloS one · 2021Article
- Epidemiological Study ofFrontiers in microbiology · 2021Article
- Immune Alterations in a Patient with SARS-CoV-2-Related Acute Respiratory Distress Syndrome.Journal of clinical immunology · 2020Article
- Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis?Medical hypotheses · 2020Article
- Preceding infection and risk of stroke: An old concept revived by the COVID-19 pandemic.International journal of stroke : official journal of the International Stroke Society · 2020Review
- Neurological manifestations of COVID-19, SARS and MERS.Acta neurologica Belgica · 2020Review
- Evolutionary genetics of canine respiratory coronavirus and recent introduction into Swedish dogs.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2020Article
- Middle East Respiratory Syndrome Coronavirus (MERS-CoV): State of the Science.Microorganisms · 2020Review
- Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)?PLoS pathogens · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronaviruses have traditionally been associated with mild upper respiratory tract infections throughout the world. In the fall of 2002, a new coronavirus emerged in in Asia causing severe viral pneumonia, i.e., severe acute respiratory syndrome (SARS). Nearly a decade following the SARS epidemic, a new coronavirus causing severe viral pneumonia has emerged, i.e., middle east respiratory syndrome (MERS). Since the initial case of MERS-CoV occurred in June of 2012 in Saudi Arabia there have been 688 confirmed cases and 282 deaths in 20 countries. Although both SARS and MERS are caused by coronaviruses, SARS was characterized by efficient human transmission and relatively low mortality rate. In contrast, MERS is relatively inefficiently transmitted to humans but has a high mortality rate. Given the potential overlap in presentation and manifestation, it is important to understand the clinical and epidemiologic differences between MERS, SARS and influenza.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.